Eisai has joined forces with Oita University in Japan to develop a machine-learning tool that may be able to predict whether someone is at risk of developing Alzheimer’s d
Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than
A just-published report has found that more than a third (36%) of people currently living with dementia in the UK are undiagnosed, and major changes are needed to overturn
A large-scale study that will pilot the use of blood tests to diagnose Alzheimer’s disease has been announced in the UK, in the hope of finding ways to spot people in the
Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing
Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.